Zanidatamab: reshaping the treatment landscape for HER2-positive gastroesophageal adenocarcinoma

Authors
Category Primary study
JournalMemo Mag. Euro. Med. Oncol.
Year 2026
This article has no abstract
Epistemonikos ID: 54523a34c3558a4e7b257746eacc1b120f47952a
First added on: Oct 17, 2026